December 09, 2016 2:44 AM ET

Healthcare Equipment and Supplies

Company Overview of Medafor, Inc.

Company Overview

Medafor, Inc. develops and markets haemostatic products based on engineered biopolymeric microporous particles in the United States and internationally. The company offers AristaAH, an absorbable surgical hemostat product that is used in the control of profuse bleeding in general surgery; FlexiTip, a spray applicator for the management of bleeding or profuse following topical ENT surgical procedures; and TraumaDEX, a topical dressing for the control of severely bleeding wounds from traumatic injuries, including cuts, lacerations, and puncture wounds. The company also provides SafeSeal and MPatcH that are topical adhesive wound dressings for the local management and control of bleeding from v...

2700 Freeway Boulevard

Suite 800

Minneapolis, MN 55430

United States

Founded in 1999





Key Executives for Medafor, Inc.

Chief Executive Officer
Compensation as of Fiscal Year 2016.

Medafor, Inc. Key Developments

CryoLife Resolves Patent Litigation with Medafor over Blood-Clotting Agent Perclot

CryoLife reported it resolved a patent dispute with CR Bard's (BCR) subsidiary Medafor over blood-clotting agent PerClot. Under the terms of the resolution, both companies agreed to dismiss all claims and waive all appeal rights. CryoLife noted that a preliminary injunction forbidding it to market and sale PerClot in the U.S. will remain in effect until Medafor's related patent expires on Feb. 8, 2019.

CryoLife Provides Update on PerClot Litigation

CryoLife, Inc. provided an update on its ongoing litigation with C.R. Bard, Inc. and certain of its subsidiaries regarding PerClot. The U.S. District Court for the District of Delaware has allowed CryoLife's declaratory judgment lawsuit against C.R. Bard's Medafor, Inc. subsidiary to proceed. The Court also granted Medafor's motion for a preliminary injunction with respect to CryoLife's marketing and sale of PerClot Topical in the U.S. CryoLife is currently awaiting the Court's order, which it expects will provide details regarding the scope of the injunction. In April 2014, CryoLife filed a declaratory judgment lawsuit against C.R. Bard and certain of its subsidiaries, including Medafor, requesting that the Court declare that CryoLife's manufacture, use, offer for sale, and sale of PerClot in the U.S. does not and would not infringe Medafor's U.S. Patent No. 6,060,461. In addition CryoLife requested that the Court declare that the claims of the '461 Patent are invalid. In September 2014, Medafor filed a motion for a preliminary injunction against CryoLife.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Medafor, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at